Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Analysis of Circulating Tumor Markers in the Blood

Trial Profile

Analysis of Circulating Tumor Markers in the Blood

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Pembrolizumab (Primary) ; Everolimus; Fulvestrant; Palbociclib
  • Indications Advanced breast cancer; Bone cancer; Colorectal cancer; HER2 positive breast cancer; Lung cancer; Non-small cell lung cancer; Sarcoma; Soft tissue sarcoma; Solid tumours; Triple negative breast cancer; Uveal melanoma
  • Focus Biomarker; Proof of concept; Therapeutic Use
  • Acronyms ALCINA
  • Most Recent Events

    • 01 Apr 2024 Results assessing the efficacy of fulvestrant and everolimus in CDK4/6i pre-treated mBC patients and circulating tumor DNA (ctDNA) changes throughout therapy, published in the Oncogene
    • 16 Nov 2023 Results assessing prognostic value of three liquid biopsy analytes (CTCs, sEVs, and ctDNA), alone and in combination in patient samples (n=54) from this study published in the British Journal of Cancer.
    • 05 Sep 2023 Planned End Date changed from 1 Jul 2024 to 1 Sep 2025.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top